Turning Point Brands (TPB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 8, 2025, with stockholders able to participate and vote online.
Key proposals include electing ten directors, amending the Certificate of Incorporation to limit officer liability, ratifying KPMG LLP as auditor, and an advisory vote on executive compensation.
The Board recommends voting in favor of all proposals and emphasizes increased board diversity and responsiveness to stockholder feedback.
Voting matters and shareholder proposals
Stockholders will vote on electing ten directors for one-year terms, an amendment to limit officer liability, ratification of KPMG LLP as auditor, and a non-binding say-on-pay vote.
The Board recommends voting “FOR” all proposals.
Stockholder proposals for the 2026 meeting must be submitted by November 24, 2025, to be included in proxy materials.
Board of directors and corporate governance
The Board expanded from nine to ten members, adding Kathleen Shanahan, with a focus on increasing diversity and expertise.
A majority of directors and nominees self-identify as women or people of color.
The Board has three standing committees: Audit, Compensation, and Nominating and Governance, all composed of independent directors.
Board leadership includes an Executive Chairman, CEO, and Lead Independent Director to ensure independent oversight.
Directors receive annual cash retainers and RSUs; committee chairs and the Lead Independent Director receive additional compensation.
Latest events from Turning Point Brands
- Modern Oral net sales jumped 266%, driving 29% overall revenue growth and strong 2026 outlook.TPB
Q4 20252 Mar 2026 - Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 20242 Feb 2026 - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 202415 Jan 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Key votes include director elections, auditor change, officer liability limits, and executive pay approval.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025 - Modern Oral sales soared 628% year-over-year, driving record Q3 growth and raised guidance.TPB
Q3 202513 Nov 2025